SPI Infoamtion

Table of Contents

Executive Summary

Overview and epidemiology of pain
Global market analysis
Pipeline analysis
Competitive landscape

Chapter 1 Scope and methodology

Scope
Methodology

Chapter 2 Overview and epidemiology of pain

Summary
Introduction
Neuropathic pain

Lower back pain

Background
Diagnosis, treatment and management
Epidemiology

Neuralgia/fibromyalgia

Background
Diagnosis, treatment and management
Epidemiology

Diabetic neuropathic pain

Background
Diagnosis, treatment and management
Epidemiology

Pain associated with multiple sclerosis

Background
Diagnosis, treatment and management
Epidemiology

Nociceptive pain

Arthritic pain

Background
Diagnosis, treatment and management
Epidemiology

Post-operative pain

Background
Diagnosis, treatment and management
Epidemiology

Cancer-related pain

Background
Diagnosis, treatment and management
Epidemiology

HIV/AIDS-related pain

Background
Diagnosis, treatment and management
Epidemiology

Chapter 3 Global market analysis

Summary
Introduction
Key events

Revival of Mundipharma's OxyContin CR sales followin out-ofcourt settlements
Mylan's fentanyl patches may succeed where J&J's Duragesic failed
OGD loosens requirements for generic lidocaine patches
M&A and licensing deals to drive the global pain management market

Regional dynamics
Market analysis by drug class
Leading brands in the global pain market
Analgesics

Analgesics market analysis by drug class
Leading brands in the analgesics market
Leading players in the analgesics market
Analgesic drug classes

Narcotic analgesics
Non-narcotic analgesics

Analgesics sales forecasts

Anticonvulsants

Leading brands in the anticonvulsants market
Leading players in the anticonvulsants market
Anticonvulsants sales forecasts

Non-steroidal anti-inflammatory drugs

NSAIDs market analysis by drug class
Leading brands in the NSAIDs market
Leading players in the NSAIDs market
NSAID classes

Anti-rheumatic NSAIDs
Coxibs

NSAIDs sales forecasts

Local anesthetics

Local anesthetics market analysis by medical applications
Leading brands in the local anesthetics market
Leading players in the local anesthetics market
Local anesthetics sales forecasts

Global pain management sales forecasts

Chapter 4 Pipeline analysis

Summary
Introduction
R&D trends

Reduced R&D activity from leading drug companies
Innovative drug delivery formulations and reformulations
Development of products associated with better side effect profiles
Flexibility in titration and dosing
Entry of biologics into the pain management space
Trial data bridging may reduce the number of studies required for EU approval

Leading products in development

New chemical entities

Tapentadol
Tanezumab
Naproxcinod
Ralfinamide

Novel formulations

Remoxy
Embeda
Onsolis
Diractin
Rapinyl/Abstral
Eladur

Pipeline sales forecasts

Chapter 5 Competitive landscape

Summary
Introduction

Sales performance of leading players

Forecast sales performance of the leading players

Pfizer

Overview
Drug class focus
Key brands
Pipeline portfolio
Strategic and growth analysis

J&J

Overview
Drug class focus
Key brands
Pipeline portfolio
Strategic and growth analysis

Novartis

Overview
Drug class focus
Key brands
Strategic and growth analysis

GlaxoSmithKline

Overview
Drug class focus
Key brands
Strategic and growth analysis

Mundipharma

Overview
Drug class focus
Key brands
Strategic and growth analysis

Abbott

Overview
Drug class focus
Key brands
Strategic and growth analysis

Sanofi-Aventis

Overview
Drug class focus
Key brands
Strategic and growth analysis

UCB

Overview
Drug class focus
Key brands
Strategic and growth analysis

Teva

Overview
Drug class focus
Key brands
Strategic and growth analysis

Endo Pharma

Overview
Drug class focus
Licensing deals
Key brands
Strategic and growth analysis

Chapter 6 Appendix

IMS Data

M1A1 Antirheumatics non-steroidal plain
M1A2 Antirheumatics non-steroidal combination
M1A3 Coxibs plain
N1B1 Anesthetics local medical injection
N1B2 Anaesthetics local dental injection
N1B3 Anaesthetics local topical
N1B9 Anaesthetics local others
N2A0 Narcotic analgesics
N2B0 Non-narcotic analgesics
N2B1 Non-narcotic analgesics, prescription
N2B2 Non-narcotic analgesics, OTC
N3A0 Anti-epileptics

Glossary
Index

List of Figures
Figure 2.1: Factors involved in pain sensation
Figure 3.2: Regional shares (%) of the pain management market,2007
Figure 3.3: Clinical profile of OxyContin CR
Figure 3.4: Clinical profile of Duragesic
Figure 3.5: Clinical profile of Topamax
Figure 3.6: Clinical profile of Lamictal
Figure 3.7: Clinical profile of Lyrica
Figure 3.8: Clinical profile of Voltaren
Figure 3.9: Clinical profile of Celebrex
Figure 3.10: Clinical profile of Lidoderm
Figure 4.11: Leading recently launched products and late-stage R&D compounds indicated for the treatment of pain, 2009
Figure 4.12: "Abuse-deterrent" formulation design of Embeda
Figure 5.13: Market dynamics of leading players in the global pain management market, 2006-07

List of Tables
Table 2.1: Estimated prevalence of neuropathic and nociceptive pain in the seven major pharmaceutical markets,2008
Table 2.2: Estimated prevalence of neuropathic lower back pain in the seven major pharmaceutical markets,2008
Table 2.3: Forecast prevalence of neuropathic lower back pain across the seven major markets,2008-14
Table 2.4: Estimated prevalence of neuralgia/fibromyalgia pain in the seven major pharmaceutical markets, 2008
Table 2.5: Forecast prevalence of neuralgia/fibromyalgia across the seven major markets, 2008-14
Table 2.6: Estimated prevalence of diabetic neuropathic pain in the seven major pharmaceutical markets, 2008
Table 2.7: Forecast prevalence of diabetic neuropathic pain across the seven major markets,2008-14
Table 2.8: Estimated prevalence of multiple sclerosis in the seven major pharmaceutical markets,2008
Table 2.9: Forecast prevalence of pain associated with multiple sclerosis across the seven major markets, 2008-14
Table 2.10: Estimated prevalence of OA-related pain in the seven major pharmaceutical markets,2008
Table 2.11: Estimated prevalence of RA pain in the seven major pharmaceutical markets, 2008
Table 2.12: Forecast prevalence of OA-related pain across the seven major markets, 2008-14
Table 2.13: Forecast prevalence of RA-related pain across the seven major markets, 2008-14
Table 2.14: Estimated prevalence of post-operative pain in the seven major pharmaceutical markets, 2008
Table 2.15: Forecast prevalence of post-operative pain across the seven major markets, 2008-14
Table 2.16: Estimated prevalence of cancer-related pain in the seven major pharmaceutical markets, 2008
Table 2.17: Forecast prevalence of early-stage cancer-related pain across the seven major markets,2008-14
Table 2.18: Forecast prevalence of late-stage cancer-related pain across the seven major markets,2008-14
Table 2.19: Estimated prevalence of HIV/AIDS-related neuropathic pain in the seven major pharmaceutical markets, 2008
Table 2.20: Forecast prevalence of HIV/AIDS-related pain across the seven major markets, 2008-14
Table 3.21: Licensing deals in the global pain management market
Table 3.22: Break-up of the global pain management market by drug class, 2006-07
Table 3.23: Leading brands in the global pain management market, 2006-07
Table 3.24: Drug classes in the global analgesics market, 2006-07
Table 3.25: Leading brands in the global analgesics market, 2006-07
Table 3.26: Leading players in the global analgesics market, 2006-07
Table 3.27: Leading brands in the global narcotic analgesics market, 2006-07
Table 3.28: Leading brands in the global non-narcotic analgesics market, 2006-07
Table 3.29: Competitive analysis of Tylenol and Efferalgan
Table 3.30: Sales forecasts of analgesics, 2007-14
Table 3.31: Leading brands in the global anticonvulsants market, 2006-07
Table 3.32: Leading anticonvulsant brands based on proportion of sales generated by prescriptions for pain indications in the seven major markets, 2007
Table 3.33: Leading players in the global anticonvulsants market, 2006-07
Table 3.34: Sales forecast for the anticonvulsants, 2007-14
Table 3.35: Drug classes in the global NSAIDs market, 2006-07
Table 3.36: Leading brands in the global NSAIDs market, 2006-07
Table 3.37: Leading players in the global NSAIDs market, 2006-07
Table 3.38: Leading brands in the global anti-rheumatic NSAIDs market, 2006-07
Table 3.39: Leading brands in the global coxibs market, 2006-07
Table 3.40: Sales forecasts of NSAIDs, 2007-14
Table 3.41: Medical applications in the global local anesthetics market, 2006-07
Table 3.42: Leading brands in the global local anesthetics market, 2006-07
Table 3.43: Leading players in the global local anesthetics market, 2006-07
Table 3.44: Sales forecasts of local anesthetics, 2007-14
Table 3.45: Sales forecasts of the global pain management market, 2007-14
Table 4.46: An overview of tapentadol
Table 4.47: An overview of tanezumab
Table 4.48: An overview of naproxcinod
Table 4.49: An overview of ralfinamide
Table 4.50: An overview of Remoxy
Table 4.51: An overview of Embeda
Table 4.52: An overview of Onsolis
Table 4.53: An overview of Diractin
Table 4.54: An overview of Rapinyl/Abstral
Table 4.55: An overview of Eladur
Table 4.56: Sales forecasts of pipeline compounds, 2007-14
Table 5.57: Leading companies in the global pain management market,
Table 5.58: Pain management sales forecasts of the leading players in the market, 2007-14
Table 5.59: Pfizer's pain management sales break-up based on drug class, 2007
Table 5.60: Pfizer's leading pain management products, 2006-07
Table 5.61: Pfizer's key pain management products under development, March 2009
Table 5.62: J&J's pain management sales break-up based on drug class, 2007
Table 5.63: J&J's leading pain management products, 2006-07
Table 5.64: J&J's key pain management products under development,
Table 5.65: Novartis's pain management sales break-up based on drug class, 2007
Table 5.66: Novartis's leading pain management products, 2006-07
Table 5.67: GSK's pain management sales break-up based on drug class, 2007
Table 5.68: GSK's leading pain management products, 2006-07
Table 5.69: Mundipharma's pain management sales break-up based on drug class, 2007
Table 5.70: Mundipharma's leading pain management products, 2006-07
Table 5.71: Abbott's pain management sales break-up based on drug class, 2007
Table 5.72: Abbott's leading pain management products, 2006-07
Table 5.73: Sanofi-Aventis's pain management sales break-up based on drug class, 2007
Table 5.74: Sanofi-Aventis's leading pain management products, 2006-07
Table 5.75: UCB's pain management sales break-up based on drug class, 2007
Table 5.76: UCB's leading pain management products, 2006-07
Table 5.77: Teva's pain management sales break-up based on drug class, 2007
Table 5.78: Teva's leading pain management products, 2006-07
Table 5.79: Endo's pain management sales break-up based on drug class, 2007
Table 5.80: Endo's US pain management marketing licensing deals
Table 5.81: Endo's leading pain management products, 2006-07